Hope on the Horizon: How Dual Therapy is Reshaping Childhood Brain Cancer Treatment
A groundbreaking study from the Children’s Cancer Institute and UNSW Sydney is offering a beacon of hope for children battling diffuse midline gliomas (DMG), including the particularly aggressive diffuse intrinsic pontine glioma (DIPG). Researchers have discovered that combining two new-generation drugs – epigenetic therapies – shows significant promise in lab studies and animal models, potentially offering a more effective approach than single-drug treatments.
The Challenge of Childhood Brain Cancer
Childhood brain cancer is a devastating diagnosis. DIPG, in particular, carries a grim prognosis, with children typically surviving only around 12 months after diagnosis. The complexity lies in the sheer number of genes simultaneously driving tumor growth. Traditional approaches struggle to address this widespread genetic disruption. According to the National Cancer Institute, brain and other central nervous system tumors are the most common cancer in children, accounting for about 28% of all childhood cancers.
Epigenetic Therapies: A New Approach
Epigenetic therapies represent a shift in cancer treatment. Unlike traditional chemotherapy that directly targets DNA, these drugs influence how genes are expressed – essentially controlling which genes are “switched on” or “off.” This is achieved by interfering with transcription, the process cells use to read genes and create proteins. This approach offers a more nuanced way to disrupt cancer growth without directly altering the genetic code.
FACT and BET: The Dynamic Duo
The study focused on two key proteins involved in transcription: FACT and BET. These proteins are often found in high concentrations within cancer cells, fueling their uncontrolled growth. While drugs targeting these proteins individually have shown limited success, the combination proved remarkably effective. Lab experiments demonstrated that blocking both FACT and BET led to cancer cell death, and in mice, it slowed tumor growth and extended lifespan.
Boosting the Immune Response
Interestingly, the dual therapy also triggered signals that activate the immune system. This is a crucial finding, as it suggests the treatment could make cancer cells more visible to the body’s natural defenses. Researchers are now exploring the potential of combining this dual therapy with immunotherapies, such as CAR T-cell therapy, to further enhance the immune response. A 2023 study published in Nature Medicine showed promising results with CAR T-cell therapy in a small group of children with relapsed or refractory DMG, highlighting the potential of immunotherapy in this space.
The Future of Pediatric Brain Cancer Treatment
While the current research is still in its early stages, it provides a strong foundation for future clinical trials. Both the FACT inhibitor (CBL0137) and potential BET inhibitors are already undergoing safety testing in children. The next step is to identify the optimal BET inhibitor to pair with CBL0137 and then launch a clinical trial specifically for children with DMG.
Beyond DMG: Potential Applications in Other Cancers
The principles behind this dual therapy approach aren’t limited to DMG. Researchers believe that disrupting transcription could be effective against other cancers characterized by widespread genetic dysregulation. Studies are underway to investigate the potential of this combination in other pediatric and adult cancers.
Personalized Medicine and Biomarker Discovery
The future of cancer treatment is increasingly personalized. Identifying biomarkers – specific genetic or molecular characteristics – that predict a patient’s response to therapy will be crucial. Researchers are actively working to identify biomarkers that can help determine which children with DMG are most likely to benefit from this dual therapy approach.
Frequently Asked Questions
Q: What is diffuse midline glioma (DMG)?
A: DMG is a type of childhood brain cancer that occurs in the central part of the brain. It’s often difficult to treat and has a poor prognosis.
Q: What are epigenetic therapies?
A: Epigenetic therapies are drugs that affect how genes are turned on and off, without changing the DNA itself.
Q: When will this treatment be available for patients?
A: While promising, this treatment is still in the early stages of development. Clinical trials are needed before it can be widely available.
Q: How does this therapy differ from traditional chemotherapy?
A: Traditional chemotherapy directly damages DNA, while epigenetic therapies influence gene expression. This can lead to fewer side effects and a more targeted approach.
To learn more about childhood brain cancer research and support organizations, visit the websites of the Children’s Cancer Institute (https://www.ccia.org.au/) and the National Brain Tumor Society (https://braintumor.org/).
Share your thoughts! What are your hopes for the future of childhood cancer treatment? Leave a comment below.
Worth a look